Skip to main content
Medical information Clinical review pending

Genetic Testing

RET Gene Multiple Endocrine Neoplasia Type 2A Genetic Test

Genetic test using Next Generation Sequencing (NGS) to identify mutations in the RET gene associated with Multiple Endocrine Neoplasia Type 2A (MEN2A), a condition linked to specific cancers.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. Confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the RET Gene Multiple Endocrine Neoplasia Type 2A Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of Multiple Endocrine Neoplasia Type 2A (MEN2A).
  • ✓Family history of medullary thyroid carcinoma (MTC).
  • ✓Personal history of MTC.
  • ✓Personal history of pheochromocytoma.
  • ✓Personal history of primary hyperparathyroidism.
  • ✓Individuals with unexplained endocrine abnormalities suggestive of MEN2A.
02

In plain language

What this test helps you understand

Identifies individuals with pathogenic RET gene variants associated with MEN2A, enabling early diagnosis, surveillance, and management of associated endocrine tumors like medullary thyroid carcinoma and pheochromocytoma.
The RET Gene Multiple Endocrine Neoplasia Type 2A (MEN2A) Genetic Test is designed to detect mutations in the RET gene. These mutations are known to increase the risk of developing MEN2A, a condition that can lead to medullary thyroid carcinoma, pheochromocytoma, and primary hyperparathyroidism. This test uses advanced Next Generation Sequencing (NGS) technology to analyze your DNA for these specific genetic changes. Understanding your genetic risk is important for proactive health management and early detection strategies. This test is particularly relevant for individuals with a family history of MEN2A or related endocrine tumors.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. Confirm with the laboratory for any specific instructions.
SampleBlood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the RET gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific mutations in the RET gene known to be associated with MEN2A. It may not detect all possible mutations or other genetic factors contributing to endocrine tumors. A negative result does not completely rule out the risk. Interpretation requires clinical correlation.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Multiple Endocrine Neoplasia Type 2A (MEN2A) is an inherited condition that increases the risk of developing certain types of endocrine tumors, primarily medullary thyroid carcinoma, pheochromocytoma, and primary hyperparathyroidism.
Individuals with a family history of MEN2A or related tumors, or those with personal symptoms or diagnoses suggestive of the condition, should consider testing. Genetic counseling is recommended.
A positive result indicates the presence of a RET gene mutation associated with MEN2A. This means you have an increased risk of developing related tumors and should discuss surveillance and management options with your doctor.
A negative result means no known MEN2A-associated mutations were detected in the RET gene. While this lowers the likelihood, it doesn't completely eliminate the risk, especially if family history is strong.
Results should be interpreted by a qualified healthcare professional, such as a genetic counselor or oncologist, who can consider your personal and family medical history.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp